TRANZ INJECTION
November 10, 2017TAZOMED 4.5 g INJECTION
November 10, 2017
| ENOVA 40/60 |
Enoxaparin Sodium Inj. |
|
| Composition : |
40 mg/0.4 ml: Each pre filled syringe contains Enoxaparin sodium Eq. to 40 mg Enoxaparin in water for injection (q.s).
60 mg/0.4 ml: Each pre filled syringe contains Enoxaparin sodium Eq. to 60 mg Enoxaparin in water for injection (q.s). |
| Indications : |
- The prophylaxis of thromboembolic disorders of venous origin, in particular those which may be associated with orthopedic or general surgery.
- The prophylaxis of venous thromboembolism in medical patients bedridden due to illness.
- The treatment of venous thromboembolic disease presenting with deep vein thrombosis, Pulmonary embolism or both.
- The treatment of unstable angina and non-Q-wave myocardial infarction, administered concurrently with aspirin.
- Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) including patients to be managed medically or with subsequent Percutaneous Coronary
- Intervention (PCI) in conjunction with thrombolytic drugs (fibrin or non-fibrin specific).
- The prevention of thrombus formation in the extracorporeal circulation during haemodialysis.
|
| Contraindications : |
- Hypersensitivity to enoxaparin sodium, heparin or its derivatives, including other low molecular weight heparins (LMWH) or to any of the excipients.
- History of immune mediated heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies
- Active clinically significant bleeding and conditions with a high risk of haemorrhage, including recent haemorrhagic stroke, gastrointestinal ulcer, presence of malignant neoplasm at high risk of bleeding, recent brain, spinal or ophthalmic surgery, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
|
| Dosage : |
- In patients at moderate risk of thromboembolism, the recommended dose of enoxaparin sodium is 2,000 IU (20 mg) once daily by subcutaneous (SC) injection.
- In moderate risk patients, enoxaparin sodium treatment should be maintained for a minimal period of 7-10 days whatever the recovery status (e.g. mobility). Prophylaxis should be continued until the patient no longer has significantly reduced mobility.
- In patients at high risk of thromboembolism, the recommended dose of enoxaparin sodium is 4,000 IU (40 mg) once daily given by SC injection preferably started 12 hours before surgery. If there is a need for earlier than 12 hours enoxaparin sodium preoperative prophylactic initiation (e.g. high risk patient waiting for a deferred orthopaedic surgery), the last injection should be administered no later than 12 hours prior to surgery and resumed 12 hours after surgery.
|
